Michael Barbella, Managing Editor10.21.22
Penumbra Inc. and Asahi Intecc Co. are teaming up to improve embolism treatment in Japan.
The two companies are working together to introduce Penumbra’s Indigo Aspiration System into the Japanese market upon regulatory approval.
“By bringing together our newest innovations with Asahi’s leadership and expertise in the Japanese medical device market, we can provide physicians in Japan with technology that has been proven highly effective, helping patients return home quickly and in good health,” Penumbra President/CEO Adam Elsesser said. “This furthers our commitment to advance novel technologies to address unmet needs and improve patient care worldwide.”
Penumbra’s Indigo Aspiration System is used to remove emboli and thrombi from vessels of the peripheral arterial and venous systems, and for treating pulmonary embolism. A minimally-invasive device, Indigo enables the restoration of blood flow in such cases as acute limb ischemia and venous thrombus. Penumbra’s newest generation offering combines hypotube-based Indigo Aspiration Catheters with Lightning Intelligent Aspiration, a unique computer-aided clot detection technology that can differentiate between clot and blood, designed to reduce blood loss and the need for clot-dissolving drugs, which may lower the risk of bleeding complications.
“Our companies share a similar mission to help expand the available treatment options for serious conditions that impact an increasing number of people in Japan,” Asahi Intecc President/CEO Masahiko Miyata said. “We believe that, together, we are able to provide physicians with the latest innovations that best meet their patients’ needs and help advance patient care.”
Penumbra’s neurovascular thrombectomy and neurovascular and peripheral embolization devices will continue to be distributed by its partner, Medico’s Hirata. This includes the latest RED reperfusion catheters, which are designed with optimized trackability and aspiration efficiency to help navigate the complex anatomy of the brain and deliver efficient aspiration for the removal of blood clots in a broad range of stroke patients.
Headquartered in Alameda, Calif., Penumbra designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries.
The two companies are working together to introduce Penumbra’s Indigo Aspiration System into the Japanese market upon regulatory approval.
“By bringing together our newest innovations with Asahi’s leadership and expertise in the Japanese medical device market, we can provide physicians in Japan with technology that has been proven highly effective, helping patients return home quickly and in good health,” Penumbra President/CEO Adam Elsesser said. “This furthers our commitment to advance novel technologies to address unmet needs and improve patient care worldwide.”
Penumbra’s Indigo Aspiration System is used to remove emboli and thrombi from vessels of the peripheral arterial and venous systems, and for treating pulmonary embolism. A minimally-invasive device, Indigo enables the restoration of blood flow in such cases as acute limb ischemia and venous thrombus. Penumbra’s newest generation offering combines hypotube-based Indigo Aspiration Catheters with Lightning Intelligent Aspiration, a unique computer-aided clot detection technology that can differentiate between clot and blood, designed to reduce blood loss and the need for clot-dissolving drugs, which may lower the risk of bleeding complications.
“Our companies share a similar mission to help expand the available treatment options for serious conditions that impact an increasing number of people in Japan,” Asahi Intecc President/CEO Masahiko Miyata said. “We believe that, together, we are able to provide physicians with the latest innovations that best meet their patients’ needs and help advance patient care.”
Penumbra’s neurovascular thrombectomy and neurovascular and peripheral embolization devices will continue to be distributed by its partner, Medico’s Hirata. This includes the latest RED reperfusion catheters, which are designed with optimized trackability and aspiration efficiency to help navigate the complex anatomy of the brain and deliver efficient aspiration for the removal of blood clots in a broad range of stroke patients.
Headquartered in Alameda, Calif., Penumbra designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with significant unmet need. Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries.